Tiragolumab
- Generic Name
- Tiragolumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT04308785
- Locations
- 🇨🇳
Anhui Province Cancer Hospital, Hefei City, China
🇨🇳Guangxi Cancer Hospital of Guangxi Medical University, Nanning, China
🇨🇳Tianjin Cancer Hospital, Tianjin, China
A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 172
- Registration Number
- NCT04300647
- Locations
- 🇺🇸
Kaiser Permanente - Irvine, Irvine, California, United States
🇺🇸Oncology Associates of Oregon, P.C, Eugene, Oregon, United States
🇦🇺Mater Misericordiae Limited, South Brisbane, Queensland, Australia
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 620
- Registration Number
- NCT04294810
- Locations
- 🇺🇸
US oncology research at Minnesota Oncology, Saint Paul, Minnesota, United States
🇺🇸Onc & Hem Assoc SW Virginia, Salem, Virginia, United States
🇦🇺Austin Hospital Olivia Newton John Cancer Centre, Heidelberg, Victoria, Australia
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 490
- Registration Number
- NCT04256421
- Locations
- 🇺🇸
Texas Oncology Cancer Center, Austin, Texas, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Blue Ridge Cancer Care, Roanoke, Virginia, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04045028
- Locations
- 🇺🇸
Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia, United States
🇺🇸Clinical Research Alliance, Westbury, New York, United States
🇺🇸University of Pennsylvania; School of Medicine, Philadelphia, Pennsylvania, United States
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT03977467
- Locations
- 🇺🇸
Florida Cancer Specialists - East, West Palm Beach, Florida, United States
🇺🇸Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 645
- Registration Number
- NCT03869190
- Locations
- 🇪🇸
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳National Taiwan University Hospital, Yun-Lin Branch, Huwei Township, Taiwan
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
- Conditions
- Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03784326
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT03563716
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States
🇺🇸SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States
🇺🇸SCRI Florida Cancer Specialists North; Research Office North Region., Saint Petersburg, Florida, United States
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 59
- Registration Number
- NCT03554083
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.